Lymphoma Clinical Trials in Torino
31 recruitingTorino, Italy
Showing 1–20 of 31 trials
Recruiting
Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+4 more
Janssen Research & Development, LLC700 enrolled174 locationsNCT01804686
Recruiting
Phase 1Phase 2
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Diffuse Large B Cell LymphomaEwing SarcomaNeuroblastoma+2 more
Merck Sharp & Dohme LLC90 enrolled66 locationsNCT06395103
Recruiting
Phase 3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Refractory Follicular LymphomaFollicular LymphomaRelapsed/Refractory Follicular Lymphoma
Epizyme, Inc.612 enrolled229 locationsNCT04224493
Recruiting
Phase 3
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Non-small Cell Lung CancerAnaplastic Lymphoma Kinase-positive
Nuvalent Inc.450 enrolled112 locationsNCT06765109
Recruiting
Phase 1
Study of SGR-1505 in Mature B-Cell Neoplasms
High-grade B-cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+23 more
Schrödinger, Inc.98 enrolled36 locationsNCT05544019
Recruiting
Phase 2
Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients
Follicular Lymphoma
Fondazione Italiana Linfomi - ETS56 enrolled24 locationsNCT06492837
Recruiting
Phase 1Phase 2
Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients
Relapsed or Refractory Hodgkin's Lymphoma
Fondazione Italiana Linfomi - ETS122 enrolled32 locationsNCT05300282
Recruiting
Not Applicable
Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors
Classical Hodgkin LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Fondazione Italiana Linfomi - ETS552 enrolled40 locationsNCT05934084
Recruiting
Phase 2
A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)
Diffuse Large B Cell Non-Hodgkin Lymphoma
Fondazione Italiana Linfomi - ETS47 enrolled20 locationsNCT06835530
Recruiting
Phase 2
Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.
Refractory Mantle Cell LymphomaRelapsed Mantle Cell Lymphoma
Fondazione Italiana Linfomi - ETS49 enrolled21 locationsNCT05249959
Recruiting
Primary Cardiac Lymphoma: Italian Multicenter Experience
Primary Cardiac Lymphoma
Fondazione Italiana Linfomi - ETS43 enrolled17 locationsNCT05819528
Recruiting
Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial
Follicular Lymphoma
Fondazione Italiana Linfomi - ETS654 enrolled26 locationsNCT05816850
Recruiting
A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice
Non-hodgkin Lymphoma,B Cell
Fondazione Italiana Linfomi - ETS1,500 enrolled61 locationsNCT06008691
Recruiting
Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Fondazione Italiana Linfomi - ETS200 enrolled20 locationsNCT06588205
Recruiting
Phase 2
Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.
Plasmablastic Lymphoma
Fondazione Italiana Linfomi - ETS28 enrolled18 locationsNCT04915248
Recruiting
Phase 1Phase 2
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Solid TumorsAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+6 more
Incyte Biosciences International Sàrl70 enrolled25 locationsNCT03934372
Recruiting
Phase 3
Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Marginal Zone Lymphoma
The Lymphoma Academic Research Organisation260 enrolled48 locationsNCT06006117
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Follicular Lymphoma
Celgene400 enrolled160 locationsNCT06911502
Recruiting
Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma
Cutaneous T Cell LymphomaCutaneous T-Cell Lymphoma/Mycosis FungoidesCutaneous T-Cell Lymphoma/Sezary Syndrome
Fondazione Italiana Linfomi - ETS400 enrolled18 locationsNCT06588868
Recruiting
Study on Plasmablastic Lymphoma Patients
Plasmablastic Lymphoma
Fondazione Italiana Linfomi - ETS200 enrolled23 locationsNCT06781359